Griffith University’s Institute for Glycomics has been awarded $2.66 million in Ideas Grant funding from the National Health and Medical...
Four teams of expert scientists from Griffith University’s Institute for Glycomics are targeting the virus SARS-CoV-2 to discover new vaccines...
Some of Griffith University’s most outstanding researchers have been honoured at the Institute for Glycomics Research Excellence Awards evening. Attended...
Griffith University's Institute for Glycomics has announced its 2016 research excellence awards.
Griffith University’s Institute for Glycomics has developed a groundbreaking, combination vaccine that may finally beat Streptococcus A infections. Human trials are set to begin as early as next year.
Griffith University’s Institute for Glycomics has figured prominently in the National Health and Medical Research Council’s latest funding round. Announced...
Griffith launches human trials for a vaccine against Streptococcus A, the germ that causes rheumatic fever.
Griffith University has reached the milestone achievement of raising $100 million of its $125 million target as part of The Campaign to Create a Brighter Future for All.
Strep A (Streptococcus pyogenes) is a major cause of infection-related deaths, leading to over 500,000 fatalities annually. Developing countries, Indigenous populations, and vulnerable groups face the greatest risks. A potential vaccine, developed by Professor Michael Good's team at Griffith University, is undergoing human trials and shows promise in fighting multiple Strep A strains.
As Streptococcus A cases continue to be prevalent in Queensland and internationally, a new nasal vaccine could provide long-term protection from the deadly bacteria.
